Uni-Bio Science Group Ltd
00690
Company Profile
Business description
Uni-Bio Science Group Ltd is an investment holding company. It operates in three segments: Chemical pharmaceutical products, Biological pharmaceutical products, and Pipeline products. Its geographical segments are Hong Kong and China, of which all of its revenue comes from China. The company products include GeneSoft, GeneTime, Pinup, Boshutai, Bokangtai, and others. All of the company revenue is generated from PRC.
Contact
No. 20 Science Park East Avenue
Unit 502, 5th Floor, Hong Kong Science Park
Shatin, New Territories
Hong Kong
HKGT: +852 31023232
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
458
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,471.50 | 18.80 | 0.22% |
| CAC 40 | 7,282.69 | 10.37 | 0.14% |
| DAX 40 | 19,848.77 | 35.98 | -0.18% |
| Dow JONES (US) | 43,297.03 | 390.08 | 0.91% |
| FTSE 100 | 8,136.99 | 34.27 | 0.42% |
| HKSE | 20,098.29 | 215.16 | 1.08% |
| NASDAQ | 20,031.13 | 266.24 | 1.35% |
| Nikkei 225 | 39,568.06 | 437.63 | 1.12% |
| NZX 50 Index | 13,074.74 | 86.71 | 0.67% |
| S&P 500 | 6,040.04 | 65.97 | 1.10% |
| S&P/ASX 200 | 8,220.90 | 19.30 | 0.24% |
| SSE Composite Index | 3,393.53 | 42.27 | 1.26% |